FARABEGOLI, FULVIA
FARABEGOLI, FULVIA
DIPARTIMENTO DI FARMACIA E BIOTECNOLOGIE
Ricercatori
FARABEGOLI F.; F .FARABEGOLI; FARABEGOLI FU
(-)-Epigallocatechin-3-gallate down regulates estrogen receptor alpha function in MCF-7 breast carcinoma cells
2007 F. Farabegoli; C. Barbi; E. Lambertini; R. Piva
(-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
2011 Farabegoli F.; Papi A.; Orlandi M.
(-)-epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line
2010 Farabegoli F.; Papi A.; Bartolini G.; Ostan R.; Orlandi M.
A RXR ligand 6-OH-11-O-hydroxyphenanthrene with antitumour properties enhances (-)-epigallocatechin-3-gallate activity in three human breast carcinoma cell lines.
2014 Farabegoli F; Govoni M; Ciavarella C; Orlandi M; Papi A.
Betalains increase vitexin-2-O-xyloside cytotoxicity in CaCo-2 cancer cells
2017 Farabegoli, F.; Scarpa, E.S.; Frati, A.; Serafini, G.; Papi, A.; Spisni, E.; Antonini, E.; Benedetti, S.; Ninfali, P
EGCG mediated targeting of deregulated signaling pathways and non-coding rnas in different cancers: Focus on JAK/STAT, Wnt/β-catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL mediated signaling pathways
2020 Farooqi A.A.; Pinheiro M.; Granja A.; Farabegoli F.; Reis S.; Attar R.; Sabitaliyevich U.Y.; Xu B.; Ahmad A.
EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion
2017 Farabegoli, Fulvia; Govoni, Marzia; Spisni, Enzo; Papi, Alessio
Epigallocatechin-3-Gallate (EGCG) Mitigates Endothelial and Circulating Cells Alterations Following PLLA Electrospun Mat Placement
2022 Carmen Ciavarella, Ilenia Motta, Santino Blando, Sabrina Valente, Fulvia Farabegoli, Maria Letizia Focarete, Mauro Gargiulo, Gianandrea Pasquinelli
Epigallocatechin-3-gallate and 6-OH-11-O-hydroxyphenanthrene limit BE(2)-C neuroblastoma cell growth and neurosphere formation in vitro
2018 Farabegoli, Fulvia*; Govoni, Marzia; Spisni, Enzo; Papi, Alessio
Epigallocatechin-3-gallate Delivered in Nanoparticles Increases Cytotoxicity in Three Breast Carcinoma Cell Lines
2022 Farabegoli F.; Granja A.; Magalhaes J.; Purgato S.; Voltattorni M.; Pinheiro M.
Epigallocatechin-3-Gallate Delivery in Lipid-Based Nanoparticles: Potentiality and Perspectives for Future Applications in Cancer Chemoprevention and Therapy
2022 Farabegoli, Fulvia; Pinheiro, Marina
Epigallocatechin-3-gallate Increases RXRγ-mediated Pro-apoptotic and Anti-invasive Effects in Gastrointestinal Cancer Cell Lines
2016 Papi, Alessio; Govoni, Marzia; Ciavarella, Carmen; Spisni, Enzo; Orlandi, Marina; Farabegoli, Fulvia
Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways.
2012 Farabegoli F.; Vettraino M.; Manerba M.; Fiume L.; Roberti M.; Di Stefano G.
Green tea in human cancer
2005 F. Farabegoli
Lactate is a potential promoter of tamoxifen resistance in MCF7 cells
2022 Rossi V.; Govoni M.; Farabegoli F.; Di Stefano G.
Molecules Present in Plant Essential Oils for Prevention and Treatment of Colorectal Cancer (CRC)
2021 Petrocelli, Giovannamaria; Farabegoli, Fulvia; Valerii, Maria Chiara; Giovannini, Catia; Sardo, Alberto; Spisni, Enzo
Rad51/Brca2 Disruptors Inhibit Homologous Recombination and Synergize with Olaparib in Pancreatic Cancer Cells
2019 Marinella Roberti, Fabrizio Schipani, Greta Bagnolini, Domenico Milano, Elisa Giacomini, Federico Falchi, Andrea Balboni, Marcella Manerba, Fulvia Farabegoli, Francesca De Franco, Janet Robertson, Saverio Minucci, Isabella Pallavicini, Giuseppina Di Stefano, Stefania Girotto, Roberto Pellicciari, and Andrea Cavalli
Simultaneous chromosome 1q gain and 16q loss is associated with steroid receptor presence and low proliferation in breast carcinoma.
2004 F. Farabegoli; M.A.J.A. Hermsen; C. Ceccarelli; D. Santini; M.M. Weiss; G.A. Meijer and P.J. van Diest
SOCS-2 expression in MCF-7 and MDA-MB-231 cells
2008 F .Farabegoli; M. Govoni
Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma
2005 F. Farabegoli; C. Ceccarelli; D. Santini; M.Taffurelli